Amyl Therapeutics: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Amyl Therapeutics
Largest movements
- Cash -€1.7m
down €1.7m (-73.0%), from €2.3m to €616,658
mainly Investment in fixed assets (net) (-€2.9m) and Net result for the year (-€2.0m)
- Receivables within one year +€281,530
up €281,530 (+34.2%), from €822,977 to €1.1m
of which Other amounts receivable: +€286,212
- Profit (loss) carried forward -€2.0m
down €2.0m (-493%), from -€408,876 to -€2.4m
- Other debts +€645,631
up €645,631 (+11,144%), from €5,793 to €651,424
- Debts after one year -€497,108
down €497,108 (-22.3%), from €2.2m to €1.7m
of which Financial debts: -€647,519
- Trade debts +€468,409
up €468,409 (+119%), from €392,350 to €860,759
- Gross operating margin +€506,573
up €506,573 (+58.1%), from -€872,434 to -€365,861
- Financial income +€472,429
up €472,429 (+31.4%), from €1.5m to €2.0m
- Depreciation +€343,469
up €343,469 (+13.6%), from €2.5m to €2.9m
- Staff costs +€178,006
up €178,006 (+35.6%), from €499,808 to €677,814
- Financial charges +€28,065
up €28,065 (+19.4%), from €144,798 to €172,863
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €8,385,696 | €7,016,445 | -€1.4m | -16.3% |
| Fixed assets | 21/28 | €5,267,175 | €5,284,995 | +€17,820 | +0.3% |
| Intangible fixed assets | 21 | €5,021,640 | €5,030,827 | +€9,187 | +0.2% |
| Tangible fixed assets | 22/27 | €245,535 | €230,801 | -€14,734 | -6.0% |
| Plant, machinery and equipment | 23 | €31,288 | €27,501 | -€3,787 | -12.1% |
| Furniture and vehicles | 24 | €191,839 | €189,410 | -€2,428 | -1.3% |
| Other tangible fixed assets | 26 | €22,409 | €13,889 | -€8,519 | -38.0% |
| Financial fixed assets | 28 | - | €23,367 | +€23,367 | |
| Current assets | 29/58 | €3,118,521 | €1,731,450 | -€1.4m | -44.5% |
| Amounts receivable within one year | 40/41 | €822,977 | €1,104,507 | +€281,530 | +34.2% |
| Trade receivables | 40 | €4,682 | €0 | -€4,682 | -100% |
| Other amounts receivable | 41 | €818,295 | €1,104,507 | +€286,212 | +35.0% |
| Cash at bank and in hand | 54/58 | €2,283,118 | €616,658 | -€1.7m | -73.0% |
| Deferred charges and accrued income | 490/1 | €12,425 | €10,285 | -€2,140 | -17.2% |
| Total equity and liabilities | 10/49 | €8,385,696 | €7,016,445 | -€1.4m | -16.3% |
| Equity | 10/15 | €5,562,413 | €3,547,141 | -€2.0m | -36.2% |
| Contributions | 10/11 | €5,971,290 | €5,971,290 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€408,876 | -€2,424,149 | -€2.0m | -493% |
| Amounts payable | 17/49 | €2,823,282 | €3,469,304 | +€646,022 | +22.9% |
| Amounts payable after more than one year | 17 | €2,229,542 | €1,732,434 | -€497,108 | -22.3% |
| Financial debts | 170/4 | €729,542 | €82,023 | -€647,519 | -88.8% |
| Other amounts payable | 178/9 | €1,500,000 | €1,650,411 | +€150,411 | +10.0% |
| Amounts payable within one year | 42/48 | €452,918 | €1,582,229 | +€1.1m | +249% |
| Trade debts | 44 | €392,350 | €860,759 | +€468,409 | +119% |
| Suppliers | 440/4 | €392,350 | €860,759 | +€468,409 | +119% |
| Taxes, remuneration and social security | 45 | €54,775 | €70,046 | +€15,272 | +27.9% |
| Taxes | 450/3 | €5,124 | €0 | -€5,124 | -100% |
| Remuneration and social security | 454/9 | €49,650 | €70,046 | +€20,396 | +41.1% |
| Other amounts payable | 47/48 | €5,793 | €651,424 | +€645,631 | +11,144% |
| Accrued charges and deferred income | 492/3 | €140,822 | €154,641 | +€13,819 | +9.8% |
| Remuneration, social security and pensions | 62 | €499,808 | €677,814 | +€178,006 | +35.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,523,441 | €2,866,910 | +€343,469 | +13.6% |
| Other operating charges | 640/8 | €1,028 | €2,460 | +€1,432 | +139% |
| Gross operating margin | 9900 | -€872,434 | -€365,861 | +€506,573 | +58.1% |
| Operating profit (loss) | 9901 | -€3,896,711 | -€3,913,045 | -€16,334 | -0.4% |
| Financial income | 75/76B | €1,505,482 | €1,977,911 | +€472,429 | +31.4% |
| Recurring financial income | 75 | €1,505,482 | €1,977,911 | +€472,429 | +31.4% |
| Financial charges | 65/66B | €144,798 | €172,863 | +€28,065 | +19.4% |
| Recurring financial charges | 65 | €144,798 | €172,863 | +€28,065 | +19.4% |
| Profit (loss) for the period before taxes | 9903 | -€2,536,027 | -€2,107,996 | +€428,030 | +16.9% |
| Income taxes | 67/77 | -€99,426 | -€92,724 | +€6,702 | +6.7% |
| Profit (loss) for the period | 9904 | -€2,436,601 | -€2,015,273 | +€421,328 | +17.3% |
| Profit (loss) for the period to be appropriated | 9905 | -€2,436,601 | -€2,015,273 | +€421,328 | +17.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 26 October 2026 via checked.be.